ID: hyp-SDA-2026-04-09-gap-debate-20260409-2
Hypothesis
Competitive Glycan Decoys for Tau Vesicle Neutralization
Synthetic glycan mimetics that competitively bind to tau vesicle surface receptors could prevent pathological vesicle fusion and tau spreading between neurons.
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
Synthetic glycan mimetics that competitively bind to tau vesicle surface receptors could prevent pathological vesicle fusion and tau spreading between neurons. These molecular decoys would act as competitive inhibitors of disease progression.
🧬 Mechanism
🔗 Mechanism from KG for MAPT
Auto-built from this analysis's top knowledge-graph edges.
graph TD
HK1["HK1"] -->|participates in| glucose_metabolism["glucose_metabolism"]
ST6GAL1["ST6GAL1"] -->|regulates| sialylation["sialylation"]
MAPT["MAPT"] -->|participates in| vesicle_transport["vesicle_transport"]
ST6GAL1_1["ST6GAL1"] -->|catalyzes| sialylation_2["sialylation"]
LGALS3["LGALS3"] -->|regulates| autophagy["autophagy"]
MGAT5["MGAT5"] -->|catalyzes| N_glycosylation["N_glycosylation"]
glycan_patterns["glycan_patterns"] -->|characterizes| tau_vesicles["tau_vesicles"]
n2_deoxy_D_glucose_analogs["2-deoxy-D-glucose analogs"] -->|disrupts| glycosylation_patterns["glycosylation patterns"]
LGALS3_3["LGALS3"] -->|targets| tau_vesicles_4["tau_vesicles"]
MGAT5_5["MGAT5"] -->|marks| tau_vesicles_6["tau_vesicles"]
NEU1["NEU1"] -.->|inhibits| tau_aggregation["tau_aggregation"]
synthetic_glycan_mimetics["synthetic_glycan_mimetics"] -.->|inhibits| tau_spreading["tau_spreading"]
style HK1 fill:#ce93d8,stroke:#333,color:#000
style glucose_metabolism fill:#81c784,stroke:#333,color:#000
style ST6GAL1 fill:#ce93d8,stroke:#333,color:#000
style sialylation fill:#ffd54f,stroke:#333,color:#000
style MAPT fill:#ce93d8,stroke:#333,color:#000
style vesicle_transport fill:#4fc3f7,stroke:#333,color:#000
style ST6GAL1_1 fill:#ce93d8,stroke:#333,color:#000
style sialylation_2 fill:#4fc3f7,stroke:#333,color:#000
style LGALS3 fill:#ce93d8,stroke:#333,color:#000
style autophagy fill:#4fc3f7,stroke:#333,color:#000
style MGAT5 fill:#ce93d8,stroke:#333,color:#000
style N_glycosylation fill:#4fc3f7,stroke:#333,color:#000
style glycan_patterns fill:#4fc3f7,stroke:#333,color:#000
style tau_vesicles fill:#4fc3f7,stroke:#333,color:#000
style n2_deoxy_D_glucose_analogs fill:#4fc3f7,stroke:#333,color:#000
style glycosylation_patterns fill:#4fc3f7,stroke:#333,color:#000
style LGALS3_3 fill:#4fc3f7,stroke:#333,color:#000
style tau_vesicles_4 fill:#4fc3f7,stroke:#333,color:#000
style MGAT5_5 fill:#ce93d8,stroke:#333,color:#000
style tau_vesicles_6 fill:#4fc3f7,stroke:#333,color:#000
style NEU1 fill:#ce93d8,stroke:#333,color:#000
style tau_aggregation fill:#4fc3f7,stroke:#333,color:#000
style synthetic_glycan_mimetics fill:#4fc3f7,stroke:#333,color:#000
style tau_spreading fill:#4fc3f7,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix5 supports0 contradicts
Supports
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Supports
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Supports
Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.
Supports
ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids.
Supports
The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — MAPT
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MAPT.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0535
Events (7d)
0
Price History
▲6.0%💾 Resource Usage
LLM Tokens
14,284
$0.0857
Total Cost
$0.0857
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF synthetic glycan decoys (at concentrations of 10-50 μM) are applied to primary hippocampal neurons transduced with P301S tau and challenged with pathological tau seed-containing extracellular vesic | Significant reduction in extracellular tau burden measured by ELISA (total tau and phosphorylated tau-231/396 epitopes), with >40% decrease in tau seed activity | — no observation — | pending | 0.65 |
| IF rTg4510 tau transgenic mice receive intraperitoneal injections of glycan decoys (10 mg/kg, 3x/week) beginning at 2 months of age, THEN survival will be extended by >25% and rotarod performance will | Median survival increased from ~5.5 months (historical vehicle) to >6.8 months; latency to fall on accelerating rotarod (4-40 RPM over 5 min) improved by >30% a | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF synthetic glycan decoys (at concentrations of 10-50 μM) are applied to primary hippocampal neurons transduced with P301S tau and challenged with pathological tau seed-containing extracellular vesicles, THEN extracellular tau species concentration will decrease by >40% relative to vehicle control
Predicted outcome: Significant reduction in extracellular tau burden measured by ELISA (total tau and phosphorylated tau-231/396 epitopes), with >40% decrease in tau see
Falsification: No significant difference in extracellular tau levels (<20% change) between glycan decoy-treated and vehicle-treated neurons, or increased tau release indicating paradoxical enhancement of vesicular t
pendingconf 55%
IF rTg4510 tau transgenic mice receive intraperitoneal injections of glycan decoys (10 mg/kg, 3x/week) beginning at 2 months of age, THEN survival will be extended by >25% and rotarod performance will improve by >30% compared to vehicle-treated controls within 5 months of treatment initiation.
Predicted outcome: Median survival increased from ~5.5 months (historical vehicle) to >6.8 months; latency to fall on accelerating rotarod (4-40 RPM over 5 min) improved
Falsification: No significant difference in survival (hazard ratio not different, p>0.05) or rotarod performance between treatment and vehicle groups; or accelerated neurodegeneration indicated by earlier symptom on
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.